Response to Glucocorticoid Therapy in Patients with Mild to Moderate Coronavirus Disease 2019 at a Japanese Care Facility

Kikuchi, Akiko; Arita, Ryutaro; Ono, Rie; Tadano, Yasunori; Saito, Natsumi; Akaishi, Tetsuya; Kanno, Takeshi; Osawa, Minoru; Takayama, Shin; Abe, Michiaki; Onodera, Ko; Ishii, Tadashi

doi:10.1620/tjem.2022.j022

Cited by 7 publications

(5 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Isolation facilities dedicated to observing acute COVID-19 patients were present in Japan prior to May 7, 2023. Miyagi Prefecture established a facility that provided medical treatment based on patients' conditions [14]. In this facility, we conducted a project under the Tohoku University Medical Megabank Organization to store blood samples from patients requiring medical management.…”

Section: Methodsmentioning

confidence: 99%

Growth Differentiation Factor-15 Is Considered a Predictive Biomarker of Long COVID in Non-hospitalized Patients

Ono,

Takayama,

Abe

et al. 2024

Cureus

Self Cite

View full text Add to dashboard Cite

Mitochondrial dysfunction is associated with various diseases. Mitochondria plays a regulatory role during infection. The association between mitokines and subsequent COVID progression has not been previously studied. The retrospective cohort study aimed to investigate the potential of serum mitokines as long COVID biomarkers in non-hospitalized patients. Patients with confirmed SARS-CoV-2 infection and blood test reports between January 2021 and April 2023 were included. Patients were categorized into two groups, the recovered and long COVID groups, based on fatigue, decline in focus, and pain. Serum levels of growth differentiation factor 15 (GDF-15) and fibroblast growth factor-21 (FGF-21), which are affected by mitochondrial function, along with inflammatory and vascular endothelium markers, were measured using enzyme-linked immunosorbent assays (ELISA). A receiver operating characteristic curve was used to screen the biomarkers. The threshold value of GDF-15 in the acute phase was 965 pg/mL (sensitivity: 71.4%, specificity: 83.3%), indicating that GDF-15 may be associated with the presence of symptoms three months post onset. No association with inflammatory markers and vascular structures was observed. Therefore, elevated GDF-15 levels in the acute phase may act as a predictive biomarker of long COVID.

show abstract

Section: Methodsmentioning

confidence: 99%

Growth Differentiation Factor-15 Is Considered a Predictive Biomarker of Long COVID in Non-hospitalized Patients

Ono,

Takayama,

Abe

et al. 2024

Cureus

Self Cite

View full text Add to dashboard Cite

show abstract

“…In Miyagi prefecture, medical doctors in the Department of General Medicine and Kampo Medicine, Tohoku University Hospital visited the isolation facilities to check the condition of patients with poor vital signs or moderate symptoms and performed triage to decide whether to hospitalize or treat them in the isolation facilities. 13 Patients who underwent medical evaluation were checked by telephone one and two weeks after the first examination; if they had prolonged symptoms, medical examination was continued via telephone or at the hospital outpatient setting. The prescriptions were decided by the physicians according to the clinical course, physical signs, symptoms, and laboratory findings relating to each patient.…”

Section: Methodsmentioning

confidence: 99%

“…In Japan, in the early phase of the pandemic, patients with confirmed COVID‐19 who were asymptomatic or had mild symptoms were observed at isolation facilities. In Miyagi prefecture, medical doctors in the Department of General Medicine and Kampo Medicine, Tohoku University Hospital visited the isolation facilities to check the condition of patients with poor vital signs or moderate symptoms and performed triage to decide whether to hospitalize or treat them in the isolation facilities 13 . Patients who underwent medical evaluation were checked by telephone one and two weeks after the first examination; if they had prolonged symptoms, medical examination was continued via telephone or at the hospital outpatient setting.…”

Section: Methodsmentioning

confidence: 99%

Progress and treatment of “long COVID” in non‐hospitalized patients: A single‐center retrospective cohort study

Ono

Arita

Takayama

et al. 2023

Traditional & Kampo Medicine

Self Cite

View full text Add to dashboard Cite

Background“Long COVID” or “post‐COVID conditions” describes prolonged symptoms after the acute phase of coronavirus disease 2019 (COVID‐19). However, there is a paucity of published reports on its treatment.MethodThis retrospective cohort study included adult, non‐hospitalized patients with COVID‐19 symptoms at least one month after the onset who had been examined at the isolation facility in Miyagi prefecture between October 2020 and September 2021.ResultsIn total, 70 patients with a median age of 46 (21–69) years were included, and 37 were women (52.9%). The median time from onset to the end of treatment was 46 (28–396) days. Thirty‐eight patients (53.5%) showed improvement in all symptoms, while four (5.7%) did not recover within the study period. The symptoms at six months with high residual rates were dizziness (33.3%), fatigue (14.3%), myalgia (14.3%), abdominal discomfort (14.3%), and taste dysfunction (11.8%). For treatment of prolonged symptoms, formulae of Kampo medicine (Japanese traditional medicine) were used alone or in combination with Western medications in 76%, 66%, 53%, and 66% of patients at 1–2 months, 2–3 months, 3–6 months, and over 6 months respectively. Kampo formulae with anti‐inflammatory effects were used in the early period; however, tonifying formulae and blood stasis‐resolving formulae were used in the late period.ConclusionNon‐hospitalized patients with COVID‐19 may suffer from persistent symptoms after the acute phase of infection. For the management of long COVID, a comprehensive and holistic approach is needed. Kampo medicine should be considered as a treatment option for long COVID.

show abstract

“…24 пациента были госпитализи-рованы, состояние 14 улучшилось без госпитализации. Среди негоспитализированных пациентов у четырёх были неблагоприятные реакции: лёгкая бессонница (n=1) и лёгкая дисфункция печени (n=3) [35].…”

Section: компьютерная томография (ктunclassified

Factors associated with adverse outcome among hospitalized patients with moderate to severe COVID-19

Mishinova

Gomon

Kolbin

et al. 2023

GCP

View full text Add to dashboard Cite

Aims. To consider factors associated with adverse outcome among hospitalized patients with moderate and severe COVID-19.Materials and methods. Data from 345 case histories of adult patients hospitalized with moderate to severe COVID-19 were analyzed in a single-center retrospective study. Characteristics by sex, age, number of days from disease onset to admission to hospital, duration of hospitalization, duration of disease, population characteristics by medical history of comorbidities and self-medication, outcome of hospitalization and medical technologies used in hospital conditions were given for the whole cohort of patients. All parameters were analyzed using descriptive statistics methods. Qualitative variables are given in absolute (n) and relative (%) values with 95% confidence interval. Continuous variables were presented as median and quartiles. Risk factors for mortality were determined across groups using the χ2 criterion and odds ratio.Results. There was no demonstrated effect of gender, degree of pulmonary tissue lesions on computed tomography data, or time of initiation of respiratory support on disease outcome. At the same time, the age older than 65 years as well as neoplasms, type 2 diabetes mellitus, dementia, Stage 3 arterial hypertension, chronic heart failure, coronary heart disease, myocardial infarction and stroke history, chronic obstructive pulmonary disease, bronchiectatic disease, urogenital diseases were the predictors of unfavorable outcome in patients with moderate and severe COVID-19 form. Prehospital use of antiplatelet agents, direct and indirect oral anticoagulants, drugs affecting the renin-angiotensin system, systemic glucocorticosteroids, antibiotics, antiviral drugs, and analgesics was associated with a decrease in the mortality rate in patients with moderate-to-severe COVID-19, as well as timely use of pronposition and transfer to intensive care unit.Conclusions. Our findings are partially consistent with previous reports on the effect of risk factors on COVID-19 outcomes.

show abstract

Response to Glucocorticoid Therapy in Patients with Mild to Moderate Coronavirus Disease 2019 at a Japanese Care Facility

Cited by 7 publications

References 15 publications

Growth Differentiation Factor-15 Is Considered a Predictive Biomarker of Long COVID in Non-hospitalized Patients

Growth Differentiation Factor-15 Is Considered a Predictive Biomarker of Long COVID in Non-hospitalized Patients

Progress and treatment of “long COVID” in non‐hospitalized patients: A single‐center retrospective cohort study

Factors associated with adverse outcome among hospitalized patients with moderate to severe COVID-19

Contact Info

Product

Resources

About